New Results from Phase 2 Trial Confirm Benefit of : vimarsan

- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia,...

Related Keywords

United States , American , Sacituzumab Govitecan , Raj Malik , Sacituzumab Govitecan Hziy , European Society For Medical Oncology , Nasdaq , American Cancer Society , Research Triangle Park , Therapeutics Inc , Investor Relations Corporate Communications , Exchange Commission , Target Effect , Trilaciclib Reduces Rates , Multiple Adverse Events Associated , Including Neutropenia , Enrolled Patients Received Prior , Initial Objective Response Rate , Overall Study Population Consistent , Checkpoint Inhibitor Pretreated Population , Tumors Relative , Overall Study Population , Expectation Based , Enhance Anti Tumor Immunity , Currently Expected , First Quarter , Chief Medical Officer , European Society , Medical Oncology , Breast Cancer , Metastatic Triple Negative Breast Cancer , Preliminary Phase , Treatment Related Adverse Events , Metastatic Triple Negative Breast , Progression Free Survival , Triple Negative Breast Cancer , Private Securities Litigation Reform Act , System Protection , Investor Relations , Nasdaq Gthx , G1 Therapeutics ,